Dopamine rushes, withdrawals, and detoxes are trending among wellness gurus online. But experts say the science behind the ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Dopamine agonists are the first-line treatment for RLS; their efficacy has mainly been demonstrated by short-term trials of oral medications. Oertel and colleagues (2011) aimed to determine the ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

indicating that the autocrine loop of action of this hormone may be a new therapeutic target Dopamine agonists, the classical drugs used to decrease prolactin production and release from the ...

Methods: A retrospective drug utilization evaluation was conducted in patients who received levodopa or dopamine agonist for RLS from July 1, 2006, to July 31, 2007. Patients' medical records were ...

Also, there was a reduction in daytime sleepiness with the drug which if confirmed in later studies would differentiate it from dopamine agonist drugs that are sometimes used alongside L-DOPA.

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

“In the brain, GLP-1 receptors act like a stop light and tell certain areas of the brain to stop releasing dopamine ... who took a GLP-1 receptor agonist medication were less likely to be ...